Randomized, single dose, four period, cross-over open-label study to evaluate the pharmacokinetic parameters of 200 mg pirfenidone capsule versus pure pirfenidone 200 mg capsule (excluding excipients) versus 200 mg pirfenidone tablet versus 267 mg pirfenidone capsule in 32 healthy adults under fasting conditions

Trial Profile

Randomized, single dose, four period, cross-over open-label study to evaluate the pharmacokinetic parameters of 200 mg pirfenidone capsule versus pure pirfenidone 200 mg capsule (excluding excipients) versus 200 mg pirfenidone tablet versus 267 mg pirfenidone capsule in 32 healthy adults under fasting conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2016

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Pharmacokinetics
  • Sponsors AFT Pharmaceuticals
  • Most Recent Events

    • 06 Jul 2016 Status changed from not yet recruiting to completed.
    • 09 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top